Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.

Abstract

Objective: To investigate the efficacy and safety of intraperitoneal administration of recombinant human endostatin in gastric cancer with malignant ascites. Methods: Clinical data of 90 patients (37 in an Endostar® combined with cisplatin group and 53 in a cisplatin group) were retrospectively analyzed. The primary end point was overall survival, and the secondary end points were objective response rate (ORR), disease control rate (DCR) and so on. Results: Median overall survival was longer in the combination group (9.7 vs 8.1 months; p = 0.01). ORR and DCR were higher in the combination group (ORR: 75.7% vs 54.7%; p = 0.04; DCR: 94.6% vs 75.5%; p = 0.02). There were no significant differences in adverse effects between the two groups. Conclusion: Intraperitoneal administration of recombinant human endostatin improved efficacy and survival for gastric cancer with ascites.

• Authors: Zhouwei Zhan, Xiaojie Wang, Jiami Yu, Jingxian Zheng, Yi Zeng, Mingyao Sun, Li Peng, Zengqing Guo, Bijuan Chen
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 10 Pg. 1259-1271 (Mar 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 35114805 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Endostatins
• Recombinant Proteins
• endostar protein
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Ascites (drug therapy, etiology)
• Cisplatin (administration & dosage, adverse effects)
• Endostatins (administration & dosage, adverse effects)
• Female
• Humans
• Infusions, Parenteral
• Male
• Middle Aged
• Prognosis
• Quality of Life
• Recombinant Proteins (administration & dosage, adverse effects)
• Retrospective Studies
• Stomach Neoplasms (complications, drug therapy)